ZA200601324B - Benzimidazolone compounds having 5-HT4 receptor agonistic activity - Google Patents

Benzimidazolone compounds having 5-HT4 receptor agonistic activity Download PDF

Info

Publication number: ZA200601324B
Authority: ZA; South Africa
Prior art keywords: group; substituents; carbon atoms; substituted; independently selected
Prior art date: 2003-09-03

Application number

ZA200601324A

Other languages

English (en)

Inventor

Iguchi Satoru

Katsu Yasuhiro

Sone Hiroki

Uchida Chikara

Kojima Takashi

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2006-02-14

Publication date

2007-05-30

2006-02-14 Application filed by Pfizer filed Critical Pfizer

2007-05-30 Publication of ZA200601324B publication Critical patent/ZA200601324B/en

Links

108091005482 5-HT4 receptors Proteins 0.000 title description 5
230000001270 agonistic effect Effects 0.000 title description 5
150000008641 benzimidazolones Chemical class 0.000 title description 5
125000001424 substituent group Chemical group 0.000 claims description 61
125000004432 carbon atom Chemical group C* 0.000 claims description 57
150000001875 compounds Chemical class 0.000 claims description 34
125000000623 heterocyclic group Chemical group 0.000 claims description 28
125000003277 amino group Chemical group 0.000 claims description 24
125000002947 alkylene group Chemical group 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 23
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
125000000753 cycloalkyl group Chemical group 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 13
201000006549 dyspepsia Diseases 0.000 claims description 12
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 11
108020003175 receptors Proteins 0.000 claims description 11
102000005962 receptors Human genes 0.000 claims description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
125000004429 atom Chemical group 0.000 claims description 8
208000002551 irritable bowel syndrome Diseases 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
-1 hydroxytetrahydropyranyl Chemical group 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
125000001153 fluoro group Chemical group F* 0.000 claims description 5
229910052757 nitrogen Inorganic materials 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
125000004043 oxo group Chemical group O=* 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
206010010774 Constipation Diseases 0.000 claims description 4
208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
206010028813 Nausea Diseases 0.000 claims description 4
208000012902 Nervous system disease Diseases 0.000 claims description 4
208000025966 Neurological disease Diseases 0.000 claims description 4
206010030216 Oesophagitis Diseases 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
206010047700 Vomiting Diseases 0.000 claims description 4
206010003119 arrhythmia Diseases 0.000 claims description 4
230000006793 arrhythmia Effects 0.000 claims description 4
208000015114 central nervous system disease Diseases 0.000 claims description 4
208000010877 cognitive disease Diseases 0.000 claims description 4
208000010643 digestive system disease Diseases 0.000 claims description 4
208000006881 esophagitis Diseases 0.000 claims description 4
230000030135 gastric motility Effects 0.000 claims description 4
208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
230000008693 nausea Effects 0.000 claims description 4
201000002859 sleep apnea Diseases 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims 3
239000013543 active substance Substances 0.000 claims 2
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 5
229940079593 drug Drugs 0.000 description 5
102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
238000000034 method Methods 0.000 description 3
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
208000018452 Torsade de pointes Diseases 0.000 description 2
208000002363 Torsades de Pointes Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000036982 action potential Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
229960005132 cisapride Drugs 0.000 description 1
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
229960002994 dofetilide Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008406 drug-drug interaction Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
208000029493 gastroesophageal disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960004085 mosapride Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
229940125422 potassium channel blocker Drugs 0.000 description 1
239000003450 potassium channel blocker Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Ceramic Engineering (AREA)
Manufacturing & Machinery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Materials Engineering (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Structural Engineering (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200601324A 2003-09-03 2006-02-14 Benzimidazolone compounds having 5-HT4 receptor agonistic activity ZA200601324B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US50014403P	2003-09-03	2003-09-03

Publications (1)

Publication Number	Publication Date
ZA200601324B true ZA200601324B (en)	2007-05-30

Family

ID=34272920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601324A ZA200601324B (en)	2003-09-03	2006-02-14	Benzimidazolone compounds having 5-HT4 receptor agonistic activity

Country Status (39)

Country	Link
US (2)	US7776885B2 (sr)
EP (1)	EP1664036B1 (sr)
JP (1)	JP3983269B1 (sr)
KR (1)	KR100738784B1 (sr)
CN (1)	CN100482659C (sr)
AP (1)	AP2184A (sr)
AR (1)	AR045552A1 (sr)
AT (1)	ATE539077T1 (sr)
AU (1)	AU2004268840B9 (sr)
BR (1)	BRPI0414105B8 (sr)
CA (1)	CA2537127C (sr)
CR (1)	CR8267A (sr)
CY (1)	CY1112321T1 (sr)
DK (1)	DK1664036T3 (sr)
EA (1)	EA009457B1 (sr)
EC (1)	ECSP066407A (sr)
ES (1)	ES2377484T3 (sr)
GE (1)	GEP20084527B (sr)
GT (1)	GT200400174A (sr)
HR (1)	HRP20120077T1 (sr)
IL (3)	IL173705A (sr)
IS (1)	IS8289A (sr)
MA (1)	MA28021A1 (sr)
MX (1)	MXPA06002550A (sr)
NL (1)	NL1026959C2 (sr)
NO (1)	NO20061519L (sr)
OA (1)	OA13248A (sr)
PA (1)	PA8610601A1 (sr)
PE (1)	PE20050874A1 (sr)
PL (1)	PL1664036T3 (sr)
PT (1)	PT1664036E (sr)
RS (1)	RS20060145A (sr)
SI (1)	SI1664036T1 (sr)
TN (1)	TNSN06073A1 (sr)
TW (1)	TW200510332A (sr)
UA (1)	UA86204C2 (sr)
UY (1)	UY28496A1 (sr)
WO (1)	WO2005021539A1 (sr)
ZA (1)	ZA200601324B (sr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001876A (en)	1996-07-24	1999-12-14	Warner-Lambert Company	Isobutylgaba and its derivatives for the treatment of pain
GB0211230D0 (en)	2002-05-16	2002-06-26	Medinnova Sf	Treatment of heart failure
SE0301446D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
CA2537127C (en) *	2003-09-03	2011-04-05	Pfizer Inc.	Benzimidazolone compounds having 5-ht4 receptor agonistic activity
TW200533348A (en)	2004-02-18	2005-10-16	Theravance Inc	Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en)	2004-04-07	2012-11-13	Theravance, Inc.	Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en)	2004-04-07	2010-06-01	Theravance, Inc.	Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en)	2004-04-07	2011-11-01	Theravance Inc	Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en)	2004-06-15	2010-06-15	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
AU2005254800B2 (en)	2004-06-15	2010-12-09	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
DE602005016446D1 (de)	2004-11-05	2009-10-15	Theravance Inc	5-HT4-Rezeptoragonistenverbindungen
JP5042028B2 (ja)	2004-11-05	2012-10-03	セラヴァンス，インコーポレーテッド	キノリノン−カルボキサミド化合物
KR20070091665A (ko)	2004-12-22	2007-09-11	세라밴스 인코포레이티드	인다졸－카르복사미드 화합물
NZ556627A (en) *	2005-02-22	2010-09-30	Pfizer	Oxyindole derivatives as 5HT4 receptor agonists
WO2006094063A1 (en)	2005-03-02	2006-09-08	Theravance, Inc.	Quinolinone compounds as 5-ht4 receptor agonists
DE602006019213D1 (de)	2005-03-15	2011-02-10	Pfizer	Benzimidazolonderivate als cb2-rezeptor-liganden
MY147756A (en) *	2005-05-25	2013-01-15	Theravance Inc	Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ES2359673T3 (es) *	2005-06-07	2011-05-25	Theravance, Inc.	Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
ES2391107T3 (es)	2005-09-30	2012-11-21	Glaxo Group Limited	Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
EP1937670A1 (en) *	2005-09-30	2008-07-02	Glaxo Group Limited	Benzimidazolones which have activity at m1 receptor
EP1943230B1 (en) *	2005-09-30	2010-12-22	Glaxo Group Limited	Compounds which have activity at m1 receptor and their uses in medicine
WO2007053596A1 (en) *	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
MY143574A (en) *	2005-11-22	2011-05-31	Theravance Inc	Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
UY30048A1 (es) *	2005-12-23	2007-07-31	Astrazeneca Ab	Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
CA2637275C (en) *	2006-01-24	2014-12-09	R-Tech Ueno, Ltd.	Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
US20080318964A1 (en) *	2007-06-19	2008-12-25	Protia, Llc	Deuterium-enriched eszopiclone
GB0718415D0 (en) *	2007-09-20	2007-10-31	Glaxo Group Ltd	Compounds
US8642772B2 (en)	2008-10-14	2014-02-04	Sk Biopharmaceuticals Co., Ltd.	Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en)	2009-06-26	2012-07-31	Sk Biopharmaceuticals Co., Ltd.	Methods for treating drug addiction and improving addiction-related behavior
WO2011055944A2 (en)	2009-11-06	2011-05-12	Sk Holdings Co., Ltd.	Methods for treating fibromyalgia syndrome
KR101783632B1 (ko)	2009-11-06	2017-10-10	에스케이바이오팜 주식회사	주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es)	2010-02-02	2015-01-30	Novartis Ag	Derivados de ciclohexilamida como antagonistas del receptor de CRF
EP2533780B1 (en) *	2010-02-12	2017-08-23	AskAt Inc.	5-ht4 receptor agonists for the treatment of dementia
US8623913B2 (en)	2010-06-30	2014-01-07	Sk Biopharmaceuticals Co., Ltd.	Methods for treating restless legs syndrome
US9610274B2 (en)	2010-06-30	2017-04-04	Sk Biopharmaceuticals Co., Ltd.	Methods for treating bipolar disorder
US20120143119A1 (en) *	2010-12-02	2012-06-07	Lanco Biosciences, Inc.	Delivery of Serotonin Receptor Antagonists By Microinjection Systems
AR086554A1 (es)	2011-05-27	2014-01-08	Novartis Ag	Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja)	2012-05-03	2015-09-03	ノバルティスアーゲー	グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
US20180344648A1 (en) *	2015-11-30	2018-12-06	Piramal Enterprises Limited	Clobazam tablet formulation and process for its preparation
GEP20257787B (en) *	2020-10-23	2025-08-11	Hk Inno N Corp	Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US63716A (en) *		1867-04-09		Improved cheery stoner
CH566987A5 (sr) *	1972-04-21	1975-09-30	Ciba Geigy Ag
US3945953A (en) *	1972-04-21	1976-03-23	Ciba-Geigy Corporation	ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
DE3336024A1 (de) *	1983-10-04	1985-04-18	Boehringer Ingelheim KG, 6507 Ingelheim	4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) *	1987-09-23	1993-06-29	Boehringer Ingelheim Italia S.P.A.	Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0522914A1 (fr) *	1991-06-27	1993-01-13	Synthelabo	Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) *	1991-07-30	1995-05-04	Boehringer Ingelheim Italia	Derivati del benzimidazolone
GB9204565D0 (en) *	1992-03-03	1992-04-15	Smithkline Beecham Plc	Pharmaceuticals
US5300512A (en)	1992-06-24	1994-04-05	G. D. Searle & Co.	Benzimidazole compounds
US5705498A (en) *	1992-11-05	1998-01-06	Smithkline Beecham Plc.	Piperidine derivatives as 5-HT4 receptor antagonists
TW252206B (sr) *	1993-09-01	1995-07-21	Philips Electronics Nv
IT1275903B1 (it) *	1995-03-14	1997-10-24	Boehringer Ingelheim Italia	Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6207697B1 (en) *	1997-09-09	2001-03-27	Dupont Pharmaceuticals Company	Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa
US6069152A (en) *	1997-10-07	2000-05-30	Eli Lilly And Company	5-HT4 agonists and antagonists
US6420410B1 (en) *	1998-11-24	2002-07-16	Cell Pathways, Inc.	Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) *	1998-12-22	2004-01-11	Janssen Pharmaceutica Nv	4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
WO2002053568A1 (en) *	2000-12-28	2002-07-11	Mochida Pharmaceutical Co., Ltd.	Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
SE0301446D0 (sv) *	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
CA2537127C (en) *	2003-09-03	2011-04-05	Pfizer Inc.	Benzimidazolone compounds having 5-ht4 receptor agonistic activity
AU2005254800B2 (en) *	2004-06-15	2010-12-09	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) *	2004-06-15	2010-06-15	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
MY147756A (en) *	2005-05-25	2013-01-15	Theravance Inc	Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

2004
- 2004-08-20 CA CA2537127A patent/CA2537127C/en not_active Expired - Lifetime
- 2004-08-20 PL PL04744319T patent/PL1664036T3/pl unknown
- 2004-08-20 OA OA1200600069A patent/OA13248A/en unknown
- 2004-08-20 GE GEAP20049270A patent/GEP20084527B/en unknown
- 2004-08-20 SI SI200431820T patent/SI1664036T1/sl unknown
- 2004-08-20 EP EP04744319A patent/EP1664036B1/en not_active Expired - Lifetime
- 2004-08-20 KR KR1020067004335A patent/KR100738784B1/ko not_active Expired - Lifetime
- 2004-08-20 MX MXPA06002550A patent/MXPA06002550A/es active IP Right Grant
- 2004-08-20 CN CNB2004800252755A patent/CN100482659C/zh not_active Expired - Fee Related
- 2004-08-20 JP JP2006525197A patent/JP3983269B1/ja not_active Expired - Fee Related
- 2004-08-20 DK DK04744319.7T patent/DK1664036T3/da active
- 2004-08-20 UA UAA200602293A patent/UA86204C2/uk unknown
- 2004-08-20 PT PT04744319T patent/PT1664036E/pt unknown
- 2004-08-20 AU AU2004268840A patent/AU2004268840B9/en not_active Ceased
- 2004-08-20 AT AT04744319T patent/ATE539077T1/de active
- 2004-08-20 EA EA200600327A patent/EA009457B1/ru not_active IP Right Cessation
- 2004-08-20 AP AP2006003536A patent/AP2184A/xx active
- 2004-08-20 RS YUP-2006/0145A patent/RS20060145A/sr unknown
- 2004-08-20 HR HR20120077T patent/HRP20120077T1/hr unknown
- 2004-08-20 BR BRPI0414105A patent/BRPI0414105B8/pt not_active IP Right Cessation
- 2004-08-20 ES ES04744319T patent/ES2377484T3/es not_active Expired - Lifetime
- 2004-08-20 WO PCT/IB2004/002741 patent/WO2005021539A1/en not_active Ceased
- 2004-08-31 PE PE2004000831A patent/PE20050874A1/es not_active Application Discontinuation
- 2004-09-01 AR ARP040103133A patent/AR045552A1/es not_active Application Discontinuation
- 2004-09-02 GT GT200400174A patent/GT200400174A/es unknown
- 2004-09-02 TW TW093126507A patent/TW200510332A/zh unknown
- 2004-09-02 UY UY28496A patent/UY28496A1/es not_active Application Discontinuation
- 2004-09-02 PA PA20048610601A patent/PA8610601A1/es unknown
- 2004-09-02 US US10/933,629 patent/US7776885B2/en active Active
- 2004-09-03 NL NL1026959A patent/NL1026959C2/nl not_active IP Right Cessation
2006
- 2006-02-09 IS IS8289A patent/IS8289A/is unknown
- 2006-02-13 IL IL173705A patent/IL173705A/en not_active IP Right Cessation
- 2006-02-14 ZA ZA200601324A patent/ZA200601324B/en unknown
- 2006-03-02 CR CR8267A patent/CR8267A/es not_active Application Discontinuation
- 2006-03-03 MA MA28851A patent/MA28021A1/fr unknown
- 2006-03-03 EC EC2006006407A patent/ECSP066407A/es unknown
- 2006-03-03 TN TNP2006000073A patent/TNSN06073A1/en unknown
- 2006-04-03 NO NO20061519A patent/NO20061519L/no not_active Application Discontinuation
2010
- 2010-05-06 IL IL205600A patent/IL205600A0/en unknown
- 2010-05-06 IL IL205599A patent/IL205599A0/en unknown
- 2010-07-07 US US12/831,713 patent/US20100273794A1/en not_active Abandoned
2012
- 2012-02-06 CY CY20121100124T patent/CY1112321T1/el unknown

Also Published As

Publication number	Publication date
KR100738784B1 (ko)	2007-07-12
ATE539077T1 (de)	2012-01-15
JP3983269B1 (ja)	2007-09-26
PL1664036T3 (pl)	2012-04-30
PE20050874A1 (es)	2005-10-26
UY28496A1 (es)	2005-04-29
GEP20084527B (en)	2008-11-10
CN1845922A (zh)	2006-10-11
UA86204C2 (uk)	2009-04-10
GT200400174A (es)	2005-05-02
IL173705A0 (en)	2006-07-05
CN100482659C (zh)	2009-04-29
PT1664036E (pt)	2012-02-16
EP1664036A1 (en)	2006-06-07
ECSP066407A (es)	2006-09-18
CR8267A (es)	2006-11-21
SI1664036T1 (sl)	2012-03-30
CA2537127C (en)	2011-04-05
MA28021A1 (fr)	2006-07-03
IS8289A (is)	2006-02-09
CY1112321T1 (el)	2015-12-09
NO20061519L (no)	2006-06-01
AU2004268840B9 (en)	2011-02-03
TW200510332A (en)	2005-03-16
BRPI0414105A (pt)	2006-11-21
AP2006003536A0 (en)	2006-04-30
TNSN06073A1 (en)	2007-10-03
ES2377484T3 (es)	2012-03-28
MXPA06002550A (es)	2006-06-20
BRPI0414105B1 (pt)	2018-08-14
IL205600A0 (en)	2010-11-30
NL1026959A1 (nl)	2005-03-07
JP2007533613A (ja)	2007-11-22
HK1093338A1 (zh)	2007-03-02
NL1026959C2 (nl)	2006-01-23
AU2004268840A1 (en)	2005-03-10
EP1664036B1 (en)	2011-12-28
KR20060087540A (ko)	2006-08-02
IL173705A (en)	2013-04-30
US20100273794A1 (en)	2010-10-28
BRPI0414105B8 (pt)	2021-05-25
DK1664036T3 (da)	2012-02-13
AU2004268840B2 (en)	2010-09-23
IL205599A0 (en)	2010-11-30
EA200600327A1 (ru)	2006-08-25
WO2005021539A1 (en)	2005-03-10
PA8610601A1 (es)	2005-03-28
RS20060145A (sr)	2008-06-05
AP2184A (en)	2010-12-02
US20050148573A1 (en)	2005-07-07
AR045552A1 (es)	2005-11-02
HRP20120077T1 (hr)	2012-02-29
OA13248A (en)	2007-01-31
US7776885B2 (en)	2010-08-17
CA2537127A1 (en)	2005-03-10
EA009457B1 (ru)	2007-12-28

Publication	Publication Date	Title
CA2537127A1 (en)	2005-03-10	Benzimidazolone compounds having 5-ht4 receptor agonistic activity
EP2051975B1 (de)	2012-09-12	Substituierte prolinamide, deren herstellung und deren verwendung als arzneimittel
EP3265448B1 (en)	2021-12-29	Riluzole prodrugs and their use
JP6204484B2 (ja)	2017-09-27	キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物
CN100352437C (zh)	2007-12-05	哌嗪衍生物、它们的制备方法及其在制备治疗中枢神经系统(cns)疾病的药物中的应用
WO1999031073A1 (en)	1999-06-24	Novel pyrimidine-5-carboxamide derivatives
WO2001021615A1 (fr)	2001-03-29	Dérivés de benzimidazole
JP2005511478A (ja)	2005-04-28	Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
EA017919B1 (ru)	2013-04-30	Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
WO2007063925A1 (ja)	2007-06-07	２－アミノベンズアミド誘導体
CA2545092A1 (en)	2005-06-02	Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
JP5067364B2 (ja)	2012-11-07	アシルアミノピペリジン化合物
JP2007055940A (ja)	2007-03-08	ピラゾロピリミジン誘導体
EP1797076A1 (en)	2007-06-20	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007269629A (ja)	2007-10-18	キナゾリン誘導体
AU2009216149B2 (en)	2013-05-23	Amide derivative and pharmaceutical composition containing the same
SK9398A3 (en)	1998-08-05	(r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2- -methoxy-6-methylamino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
JP2004277318A (ja)	2004-10-07	１−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
KR20110080181A (ko)	2011-07-12	3-(벤질아미노)-피롤리딘 유도체 및 이의 ｎｋ-3 수용체 길항제로서의 용도
WO1999050262A1 (en)	1999-10-07	Pde iv inhibiting pyridine derivatives
JP2004277319A (ja)	2004-10-07	１−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
HUP0402357A2 (hu)	2005-02-28	Antihisztaminok alkalmazása megnövelt koponyán belüli nyomás akut csökkentésére és gyógyszerkészítmények előállítására
JP2001122784A (ja)	2001-05-08	１−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
JP4559749B2 (ja)	2010-10-13	ピペラジニルピリジン誘導体
JP5156806B2 (ja)	2013-03-06	アミド誘導体からなる医薬